AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Withdrawn before enrolling · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.

Key facts

Study ID

NCT00963365

Run by

AstraZeneca

People needed

0

Starts

2008-11-01

Expected to finish

2010-03-01

Last updated by the study team

2014-10-13

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy volunteers
• Females must be of non-childbearing potential.

You may not qualify if…

• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product.
• Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months (if half-life was < 24 hours) of the first administration of study drug
• Plasma or blood product donation within one month of screening or any blood donation/blood loss > 500mL during the 3 months prior to screening.

Where it is running

• Research Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.